Replies to post #6847 on Halozyme Therapeutics Inc (HALO)

[maumar]

$10B in 2025 is what Helen said were consensus revenue estimates for Darzalex.

The projection in your article, which has no date I can see and appears to be an old article, is $3.6bn. The $17bn refers to "drug sales for this disease" and "Darzalex(daratumumab) will be the top drug at the end of that 10-year period with $3.6bn"

"Datamonitor Healthcare's latest multiple myeloma market forecast suggests that drug sales for this disease will grow from $11.9bn in 2017 to $20.9bn in 2022 then drop each year after settling at $17bn in 2026 in the US, five major EU markets (France, Germany, Italy, Spain and the UK) and Japan. Johnson & Johnson's Darzalex(daratumumab) will be the top drug at the end of that 10-year period with $3.6bn in annual sales – one-third of Revlimid's $10.9bn peak in those markets – and Revlimid generics will come in second with $3.1bn in 2026 sales (see table below).